Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Biogen Inc (NASDAQ: BIIB) closed the day trading at $141.00 down -1.44% from the previous closing price of $143.06. In other words, the price has decreased by -$1.44 from its previous closing price. On the day, 1.55 million shares were traded. BIIB stock price reached its highest trading level at $146.15 during the session, while it also had its lowest trading level at $140.87.
Ratios:
For a better understanding of BIIB, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.55. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 1.26. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on January 02, 2025, Downgraded its rating to Neutral and sets its target price to $138 from $315 previously.
On December 20, 2024, BMO Capital Markets Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $230 to $164.
Stifel Downgraded its Buy to Hold on December 16, 2024, while the target price for the stock was maintained at $175.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 09 ’24 when Singhal Priya sold 110 shares for $157.21 per share. The transaction valued at 17,293 led to the insider holds 5,426 shares of the business.
Singhal Priya bought 110 shares of BIIB for $17,293 on Dec 09 ’24. On Sep 03 ’24, another insider, Singhal Priya, who serves as the Head of Development of the company, sold 431 shares for $204.22 each. As a result, the insider received 88,019 and left with 5,316 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 20546379776 and an Enterprise Value of 25498126336. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.74, and their Forward P/E ratio for the next fiscal year is 8.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.23 while its Price-to-Book (P/B) ratio in mrq is 1.26. Its current Enterprise Value per Revenue stands at 2.654 whereas that against EBITDA is 8.838.
Stock Price History:
The Beta on a monthly basis for BIIB is -0.07, which has changed by -0.42073935 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, BIIB has reached a high of $252.17, while it has fallen to a 52-week low of $142.42. The 50-Day Moving Average of the stock is -10.35%, while the 200-Day Moving Average is calculated to be -28.09%.
Shares Statistics:
Over the past 3-months, BIIB traded about 1.50M shares per day on average, while over the past 10 days, BIIB traded about 1217480 shares per day. A total of 145.70M shares are outstanding, with a floating share count of 144.68M. Insiders hold about 0.71% of the company’s shares, while institutions hold 89.46% stake in the company. Shares short for BIIB as of 1735603200 were 3676606 with a Short Ratio of 2.45, compared to 1732838400 on 2722956. Therefore, it implies a Short% of Shares Outstanding of 3676606 and a Short% of Float of 2.8499998.
